Business Description
Capricor Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US14070B3096
Total Employee Number:
231Compare
Compare
Traded in other countries / regions
CAPR.USA4LN2.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2002-06-20Description
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.61 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.37 | |||||
Debt-to-EBITDA | -0.72 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -21.9 | |||||
3-Year EPS without NRI Growth Rate | -25.8 | |||||
3-Year Book Growth Rate | 125.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 52.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.49 | |||||
9-Day RSI | 61.94 | |||||
14-Day RSI | 51.31 | |||||
3-1 Month Momentum % | -77.43 | |||||
6-1 Month Momentum % | -76.48 | |||||
12-1 Month Momentum % | 4.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.35 | |||||
Quick Ratio | 7.35 | |||||
Cash Ratio | 7.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -31.5 | |||||
Shareholder Yield % | -5.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.47 | |||||
ROA % | -49.36 | |||||
ROIC % | -210.69 | |||||
3-Year ROIIC % | -304.46 | |||||
ROC (Joel Greenblatt) % | -277.56 | |||||
ROCE % | -56 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 79.27 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.26 | |||||
EV-to-EBIT | -3.18 | |||||
EV-to-Forward-EBIT | -5.63 | |||||
EV-to-EBITDA | -3.24 | |||||
EV-to-Forward-EBITDA | -2.6 | |||||
EV-to-Forward-Revenue | 333.3 | |||||
EV-to-FCF | -3.16 | |||||
| Price-to-Net-Current-Asset-Value | 4.66 | |||||
| Price-to-Net-Cash | 4.82 | |||||
Earnings Yield (Greenblatt) % | -31.45 | |||||
FCF Yield % | -23.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CAPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Capricor Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.45 | ||
| Beta | 0.6181 | ||
| 3-Year Sharpe Ratio | 0.62 | ||
| 3-Year Sortino Ratio | 2.56 | ||
| Volatility % | 461.54 | ||
| 14-Day RSI | 51.31 | ||
| 14-Day ATR ($) | 1.428285 | ||
| 20-Day SMA ($) | 6.15815 | ||
| 12-1 Month Momentum % | 4.95 | ||
| 52-Week Range ($) | 2.96 - 40.37 | ||
| Shares Outstanding (Mil) | 58.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Capricor Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Capricor Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 74 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 73 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | 4.19 (+6.08%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 4.19 (+6.08%) | ||
| Guidance call for 2026 | 2026-06-27 | 26.44 (-2.79%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:00 | 26.01 (-1.92%) | ||
| General meeting for 2026 | 2026-06-04 10:00 | 27.64 (+2.26%) | ||
| Guidance call for 2026 | 2026-05-24 | 28.87 (-2.40%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 | 28.02 (-3.36%) | ||
| Guidance call for 2026 | 2026-05-15 | 29.81 (-2.26%) |
Show
Entries
Capricor Therapeutics Inc Frequently Asked Questions
What is Capricor Therapeutics Inc(CAPR)'s stock price today?
The current price of CAPR is $9.59. The 52 week high of CAPR is $40.37 and 52 week low is $2.96.
When is next earnings date of Capricor Therapeutics Inc(CAPR)?
The next earnings date of Capricor Therapeutics Inc(CAPR) is 2026-11-10 Est..
Does Capricor Therapeutics Inc(CAPR) pay dividends? If so, how much?
Capricor Therapeutics Inc(CAPR) does not pay dividend.
Press Release
Articles on Capricor Therapeutics Inc
Headlines
See More- 1
Aug 24, 2026
Capricor rises as FDA extends Deramiocel action date
Seeking Alpha • 9:27am
Aug 20, 2026
Capricor slips after report on potential Deramiocel rejection
Seeking Alpha • 9:55am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers